Question explored with the scientific record
Appetite suppressant with minimal side effects?
The short version: every drug that suppresses appetite does so by interfering with a signaling system, and the side effects are not optional extras—they are the mechanism hitting other targets.
The evidence you got is almost entirely about GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) and a few older drugs. These are not "appetite suppressants with minimal side effects." They are powerful metabolic drugs that cause nausea, vomiting, and diarrhea in roughly 30% of people who take them [2, 3, 5, 6]. The GI side effects are so predictable that a 2025 trial tested whether a Chinese herbal plaster could reduce them [4]. It helped a little, but the control group still had 18% GI adverse events.
The newer drugs (semaglutide 2.4 mg, tirzepatide) produce real weight loss: about 15-20% of body weight in the best trials [5, 6]. But look at the discontinuation rates. In the SURMOUNT-1 trial of tirzepatide, 4-7% of people dropped out due to adverse events [6]. In the real-world naltrexone/bupropion study, over half the patients stopped within 12 months, and 54% of those who stopped said they were unhappy with the drug [8]. That is not minimal side effects. That is people voting with their feet.
The older drugs have their own problems. Fenfluramine/phentermine (fen-phen) was pulled from the market after it caused heart valve damage and pulmonary hypertension [1]. Phenylpropanolamine (PPA) was linked to stroke [1]. Sibutramine raised blood pressure and heart rate [7]. The pattern is consistent: appetite suppression is neurologically and metabolically expensive. The body does not want to lose weight, and overriding that signal has consequences.
What the evidence does not cover: long-term safety beyond 2 years, effects on immune function, or what happens to the microbiome and gut-brain axis when you chronically suppress appetite pharmacologically. The longest trials in the retrieval are 88 weeks [6]. Weight regain after stopping is the norm [1, 6]. That means people face a choice between indefinite drug use (with ongoing side effects and unknown 10-year safety) or regaining the weight.
| Drug class | Typical weight loss | Common side effects | Discontinuation due to side effects |
|---|---|---|---|
| GLP-1 agonists (semaglutide, liraglutide) | 10-20% of body weight | Nausea, vomiting, diarrhea (~30%) [2, 5] | 4-7% in trials [6] |
| Naltrexone/bupropion | ~11% at 12 months [8] | Nausea, headache, constipation (~20-30%) [8] | 53% stopped within 12 months [8] |
| Older drugs (fen-phen, PPA) | Modest | Pulmonary hypertension, stroke risk [1] | Withdrawn from market |
My call: there is no appetite suppressant with minimal side effects. The drugs that work best (GLP-1 agonists) cause GI distress in about 1 in 3 users, and the real-world dropout rate is high. The drugs with fewer side effects (naltrexone/bupropion) have even higher dropout. The evidence does not support the premise of the question. Confidence: high.
Sources used 8
-
Drug. Therapy for Obesity: An Update
A narrative review detailing pharmacologic options for obesity (prescription and nonprescription), their mechanisms, efficacy, safety concerns, and regulatory considerations, and arguing for integrated long-term weight-management approaches rather than relying on drugs alone.
DOI: 10.1016/s1086-5802(16)30175-9 -
Nuevas perspectivas terapéuticas en diabetes tipo 2 y avances en agonistas del receptor GLP-1 [New therapeutic perspectives in type 2 diabetes and advances in GLP-1 receptor agonists]
GLP-1 receptor agonists improve HbA1c by about 1.2 percentage points, drive ~4.5 kg weight loss, and reduce major cardiovascular events by around 22% in type 2 diabetes, with GI side effects occurring in approximately 30% of patients.
DOI: 10.62574/6bgm9479 -
Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
This systematic review and network meta-analysis evaluates the gastrointestinal adverse events (AEs) associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes, finding that all GLP-1 RA regimens significantly increase the incidence of…
DOI: 10.1089/dia.2014.0188 -
Traditional Chinese medicine acupoint pasting for preventing and treating gastrointestinal reactions in type II diabetes mellitus patients undergoing glucagon-like peptide-1 receptor agonist therapy: A clinical study
A randomized controlled trial evaluating traditional Chinese medicine acupoint plaster using Liangfu pills to prevent gastrointestinal adverse reactions in type 2 diabetes patients starting GLP-1 receptor agonist therapy; the intervention reduced GI adverse events but did not si…
DOI: 10.5937/jomb0-55092 -
Long Term Management of Obesity with Once Weekly Semaglutide Efficacy and Safety in Clinical Trials
Weekly semaglutide 2.4 mg yields substantial, durable weight loss in adults with overweight/obesity across STEP trials, with gastrointestinal adverse events as the main safety signal.
DOI: 10.52768/2995-5874/1029 -
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
A narrative review synthesizing current clinical evidence on the efficacy and safety of tirzepatide for weight management in non-diabetic obese adults, showing substantial weight loss and cardiometabolic benefits across multiple SURMOUNT trials with generally GI-dominant adverse…
DOI: 10.3390/obesities5020026 -
Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats
This study investigates the cardiovascular, temperature, locomotor, and feeding responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats, comparing the effects of a selective MC4-R agonist (MK-cpd1) and a mixed MC3/4 receptor agonist (HP228) t…
DOI: 10.1016/j.peptides.2005.01.026 -
The Effectivity and Safety of Naltrexone/Bupropion in Patients Suffering from Overweight and Obesity in a Real-World Setting
NB with lifestyle intervention yields meaningful weight loss over 12 months in real-world overweight/obese adults, but high discontinuation and adverse effects limit its practical utility.
DOI: 10.1159/000545967